Annual EBITDA
-$205.68 M
-$59.30 M-40.51%
December 31, 2023
Summary
- As of February 7, 2025, DAWN annual EBITDA is -$205.68 million, with the most recent change of -$59.30 million (-40.51%) on December 31, 2023.
- During the last 3 years, DAWN annual EBITDA has fallen by -$192.05 million (-1409.36%).
- DAWN annual EBITDA is now -1409.36% below its all-time high of -$13.63 million, reached on December 31, 2020.
Performance
DAWN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
$30.38 M
+$144.78 M+126.56%
September 30, 2024
Summary
- As of February 7, 2025, DAWN quarterly EBITDA is $30.38 million, with the most recent change of +$144.78 million (+126.56%) on September 30, 2024.
- Over the past year, DAWN quarterly EBITDA has increased by +$89.80 million (+151.14%).
- DAWN quarterly EBITDA is now -65.03% below its all-time high of $86.88 million, reached on March 1, 2019.
Performance
DAWN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$210.08 M
+$81.72 M+28.01%
September 30, 2024
Summary
- As of February 7, 2025, DAWN TTM EBITDA is -$210.08 million, with the most recent change of +$81.72 million (+28.01%) on September 30, 2024.
- Over the past year, DAWN TTM EBITDA has dropped by -$4.40 million (-2.14%).
- DAWN TTM EBITDA is now -216.91% below its all-time high of $179.70 million, reached on September 1, 2019.
Performance
DAWN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
DAWN EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -40.5% | +151.1% | -2.1% |
| 3 y3 years | -1409.4% | +176.8% | -67.1% |
| 5 y5 years | -1279.8% | +176.8% | -67.1% |
DAWN EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -183.5% | at low | at high | +126.6% | -189.7% | +28.0% |
| 5 y | 5-year | -1409.4% | at low | at high | +126.6% | -217.0% | +28.0% |
| alltime | all time | -1409.4% | at low | -65.0% | +126.6% | -216.9% | +28.0% |
Day One Biopharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $30.38 M(-126.6%) | -$210.08 M(-28.0%) |
| Jun 2024 | - | -$114.40 M(+71.6%) | -$291.80 M(+28.8%) |
| Mar 2024 | - | -$66.65 M(+12.2%) | -$226.57 M(+10.2%) |
| Dec 2023 | -$205.68 M(+40.5%) | -$59.41 M(+15.7%) | -$205.68 M(+8.9%) |
| Sep 2023 | - | -$51.34 M(+4.4%) | -$188.83 M(+6.7%) |
| Jun 2023 | - | -$49.16 M(+7.4%) | -$177.03 M(+7.6%) |
| Mar 2023 | - | -$45.77 M(+7.5%) | -$164.45 M(+12.3%) |
| Dec 2022 | -$146.38 M(+101.8%) | -$42.56 M(+7.7%) | -$146.38 M(+16.4%) |
| Sep 2022 | - | -$39.53 M(+8.1%) | -$125.71 M(+19.3%) |
| Jun 2022 | - | -$36.59 M(+32.1%) | -$105.36 M(+25.2%) |
| Mar 2022 | - | -$27.70 M(+26.5%) | -$84.16 M(+16.1%) |
| Dec 2021 | -$72.54 M | -$21.89 M(+14.1%) | -$72.51 M(+29.2%) |
| Sep 2021 | - | -$19.18 M(+24.7%) | -$56.12 M(+37.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$15.39 M(-4.0%) | -$40.73 M(+47.1%) |
| Mar 2021 | - | -$16.04 M(+190.9%) | -$27.69 M(+103.2%) |
| Dec 2020 | -$13.63 M(-8.6%) | -$5.51 M(+45.6%) | -$13.63 M(-185.2%) |
| Sep 2020 | - | -$3.79 M(+60.9%) | $16.00 M(-81.4%) |
| Jun 2020 | - | -$2.35 M(+19.1%) | $86.09 M(-5.1%) |
| Mar 2020 | - | -$1.98 M(-108.2%) | $90.75 M(-49.5%) |
| Dec 2019 | -$14.91 M | - | - |
| Dec 2019 | - | $24.11 M(-63.6%) | $179.60 M(-0.1%) |
| Sep 2019 | - | $66.31 M(+2780.5%) | $179.70 M(+10.2%) |
| Jun 2019 | - | $2.30 M(-97.4%) | $163.08 M(-6.0%) |
| Mar 2019 | - | $86.88 M(+258.8%) | $173.47 M(+100.3%) |
| Dec 2018 | - | $24.22 M(-51.3%) | $86.60 M(+38.8%) |
| Sep 2018 | - | $49.69 M(+291.3%) | $62.38 M(+391.3%) |
| Jun 2018 | - | $12.70 M | $12.70 M |
FAQ
- What is Day One Biopharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Day One Biopharmaceuticals?
- What is Day One Biopharmaceuticals annual EBITDA year-on-year change?
- What is Day One Biopharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Day One Biopharmaceuticals?
- What is Day One Biopharmaceuticals quarterly EBITDA year-on-year change?
- What is Day One Biopharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Day One Biopharmaceuticals?
- What is Day One Biopharmaceuticals TTM EBITDA year-on-year change?
What is Day One Biopharmaceuticals annual EBITDA?
The current annual EBITDA of DAWN is -$205.68 M
What is the all time high annual EBITDA for Day One Biopharmaceuticals?
Day One Biopharmaceuticals all-time high annual EBITDA is -$13.63 M
What is Day One Biopharmaceuticals annual EBITDA year-on-year change?
Over the past year, DAWN annual EBITDA has changed by -$59.30 M (-40.51%)
What is Day One Biopharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of DAWN is $30.38 M
What is the all time high quarterly EBITDA for Day One Biopharmaceuticals?
Day One Biopharmaceuticals all-time high quarterly EBITDA is $86.88 M
What is Day One Biopharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, DAWN quarterly EBITDA has changed by +$89.80 M (+151.14%)
What is Day One Biopharmaceuticals TTM EBITDA?
The current TTM EBITDA of DAWN is -$210.08 M
What is the all time high TTM EBITDA for Day One Biopharmaceuticals?
Day One Biopharmaceuticals all-time high TTM EBITDA is $179.70 M
What is Day One Biopharmaceuticals TTM EBITDA year-on-year change?
Over the past year, DAWN TTM EBITDA has changed by -$4.40 M (-2.14%)